Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisPediatric Conditions Tagged with:American College of PhysiciansetanerceptFDAFood and Drug AdministrationGoutguidelinePediatricplaque psoriasisrituximab

2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications

Mary Beth Nierengarten  |  November 16, 2016

In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2…

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:ClinicalcomorbiditiesdrugGroup for Research and Assessment of Psoriasis and Psoriatic ArthritisguidelineManagementMedicationPsoriasisPsoriatic Arthritisrecommendationtherapy

Treating the Athlete: New Thoughts on How to Prevent & Treat Arthritis in Athletes & Raise Their Awareness

Karen Appold  |  November 4, 2016

All athletes—amateur and professional—should understand their risks for developing injury-related arthritis. Rheumatologists and other physicians at the Hospital for Special Surgery in New York take a rapid approach to treating athletes, often considering intense physical therapy, innovative treatments and surgery much sooner than for the average patient—all to keep joints healthy and enable athletes to play for as long as possible…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Exercise/physical therapyinjuryphysical fitnessPhysical Therapysecukinumab

Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

Michele B. Kaufman, PharmD, BCGP  |  October 12, 2016

A study found that ixekizumab decreases disease activity and increases physical function in biologic-naive patients with active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumab-attoIL-17ixekizumabPsoriatic Arthritis

Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  September 27, 2016

Adalimumab-atto, a biosimilar to adalimumab (Humira), has been approved by the FDA to treat multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-attoBiosimilarsFDAFood and Drug Administration

FDA Approves Ustekinumab for Crohn’s Disease

Reuters Staff  |  September 26, 2016

(Reuters)—Johnson & Johnson says on Monday that the U.S. Food and Drug Administration approved the company’s psoriasis drug, ustekinumab (Stelara), for use in adults with Crohn’s disease. The drug is approved in the U.S. to treat plaque psoriasis and a type of arthritis associated with psoriasis. Crohn’s is a chronic inflammatory condition in the gastrointestinal…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Crohn's diseaseFDAFood and Drug Administrationinflammatory bowel diseaseustekinumab

FDA Approves Adalimumab-atto, a Biosimilar of Humira

Reuters Staff  |  September 23, 2016

WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira). The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-attoBiosimilarsFDAFood and Drug Administration

Express Scripts Tries to Rein in Pricey Inflammatory Drugs

Reuters Staff  |  September 13, 2016

NEW YORK (Reuters)—Express Scripts Holding, the largest manager of U.S. drug benefits, on Thursday launched a program aimed at tightening spending on drugs for pricey inflammatory conditions such as rheumatoid arthritis. It is the latest Express Scripts effort intended to reduce spending on prescription drugs, such as last week’s announcement of a diabetes program. Early…

Filed under:Drug UpdatesPractice SupportProfessional Topics Tagged with:drug benefitsEnbrelExpress Scripts HoldingHumiraRheumatoid arthritis

Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  September 9, 2016

Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:drug updateixekizumaboutcomeproductivityPsoriasisResearchRheumatoid arthritisrheumatologySafetytrialvobarilizumab

Rheumatology Coding Corner Question: Level 4 New Patient Visit

From the College  |  September 7, 2016

A 32-year-old female patient comes in for an initial visit. She is self-referred and complains of pain, numbness and color changes in her fingers when exposed to cold. The patient reports that her right distal index finger, left distal index finger and fourth right finger turn white and blue with pain and numbness when exposed…

Filed under:Billing/CodingFrom the College Tagged with:BillingCodingoffice visitpatient carePractice Managementrheumatologistrheumatology

  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences